April 14, 2021
Business News

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020

ROCKVILLE, Md.–()–GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishments reported to date in 2021. Cash and cash equivalents at December 31, 2020 were $137.0 million.

“During 2020, we remained on track to complete enrollment of our uproleselan pivotal trial in the second half of 2021. Uproleselan continues to have strong support from collaborators working with us in the clinical and preclinical arenas. We believe this broad-based support for uproleselan reflects confidence in our approach to establish this product candidate as a potential foundational therapy across…

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
C.H. Guenther & Son Names John D. Buckles as President and Chief Executive Officer
Robotic Assistance Devices Receives 10-Unit Order from Titan Security Technologies
Former Coldwell Banker CEO Joins Houwzer Board of Directors